LTBR and pancreatic neoplasm: The addition of agonistic LTβR antibodies to anti-VEGF plus anti-PDL1 therapy, thus fully activating the LTβR signaling cues, further increased HEV numbers and maturation in breast and pancreatic cancer and sensitized glioblastoma to the therapy.